Eli Lilly Agrees to Acquire ICOS for $2.1 Billion
Indianapolis, IN (Oct. 17)-Eli Lilly and Company agreed to acquire ICOS Corporation (Bothell, WA) for $2.1 billion.
Indianapolis, IN (Oct. 17)-Eli Lilly and Company (www.lilly.com) agreed to acquire ICOS Corporation (Bothell, WA, www.icos.com) for $2.1 billion.
The companies have partnered since 1998 in Lilly ICOS LLC, a joint venture that manufactures, markets and sells “Cialis” (tadalafil), an oral PDE-5 inhibitor. Cialis had global sales of $465 million in the first half of 2006.
The deal is expected to close in late 2006 or early 2007.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
